The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases

Journal of Molecular Neuroscience, Journal Year: 2025, Volume and Issue: 75(1)

Published: March 13, 2025

Abstract Neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s (PD), multiple sclerosis (MS), and amyotrophic lateral (ALS), are characterized by the progressive gradual degeneration of neurons. The prevalence rates these disorders rise significantly with age. As life spans continue to increase in many countries, number cases is expected grow foreseeable future. Early precise diagnosis, along appropriate surveillance, continues pose a challenge. high heterogeneity neurodegenerative diseases calls for more accurate definitive biomarkers improve clinical therapy. Cell-free DNA (cfDNA), fragmented released into bodily fluids via apoptosis, necrosis, or active secretion, has emerged as promising non-invasive diagnostic tool various diseases. cfDNA can serve an indicator ongoing cellular damage mortality, neuronal loss, may provide valuable insights processes, progression, therapeutic responses. This review will first cover key aspects then examine recent advances its potential use biomarker disorders.

Language: Английский

---

Recent Advancements and Emerging Techniques in Nucleic Acid Isolation, Amplification, and Detection from Diverse Complex Matrices of Human Interest

TrAC Trends in Analytical Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 118172 - 118172

Published: Jan. 1, 2025

Language: Английский

---

Evaluation of Urinary cfDNA Workflows for Molecular Profiling of Malignant Disease

Published: Jan. 1, 2025

Language: Английский

---

Impact of Tube Additives on Baseline Cell-Free DNA, Blood Nuclease Activity, and Cell-Free DNA Degradation in Serum and Plasma Samples: A Comparative Study

LabMed, Journal Year: 2025, Volume and Issue: 2(1), P. 4 - 4

Published: March 3, 2025

Cell-free DNA (cfDNA) analysis is a pivotal tool in non-invasive diagnostics, including cancer monitoring and prenatal testing. However, the preanalytical phase, particularly choice of anticoagulant, significantly impacts cfDNA integrity yield. This study aims to compare yield, stability, DNase activity plasma-citrate plasma-heparin, using plasma-EDTA serum as established controls, explore more deeply impact blood DNAse on these specimens. Blood samples from 15 healthy volunteers were collected four types tubes (citrate, heparin, EDTA, serum). was extracted quantified qPCR, endogenous assessed through hydrolysis probe assays. Samples incubated at 37 °C for 24 h evaluate degradation rates. Heparin-plasma exhibited highest activity, with baseline levels intermediate—higher than EDTA but lower serum—leading substantial (85.3%). Combined its known PCR inhibition, this renders heparin-plasma unsuitable analysis. Citrate-plasma, similar showed partial resulting intermediate (13.3%), limitation that diminishes viability compared EDTA-plasma. Serum, levels, high significant (55.6%), making it preservation. EDTA-plasma demonstrated complete inhibition minimal (8%), confirming most suitable specimen These findings emphasize importance anticoagulant selection, highlighting critical limitations citrate-plasma while reinforcing gold standard preserving diagnostic applications.

Language: Английский

---

Application of Digital Polymerase Chain Reaction (dPCR) in Non-Invasive Prenatal Testing (NIPT)

Biomolecules, Journal Year: 2025, Volume and Issue: 15(3), P. 360 - 360

Published: March 1, 2025

This article reviews the current applications of digital polymerase chain reaction (dPCR) in non-invasive prenatal testing (NIPT) and explores its potential to complement or surpass capabilities Next-Generation Sequencing (NGS) testing. The growing incidence genetic disorders maternal–fetal medicine has intensified demand for precise accessible NIPT options, which aim minimize need invasive diagnostic procedures. Cell-free fetal DNA (cffDNA), core analyte NIPT, is influenced by numerous factors such as maternal contamination, placental health, fragment degradation. dPCR, with inherent precision ability detect low-abundance targets, demonstrates robustness against these interferences. Although NGS remains gold standard due comprehensive capabilities, high costs limit widespread use, particularly resource-limited settings. In contrast, dPCR provides comparable accuracy lower complexity expense, making it a promising alternative

Language: Английский

---

Pre‐analytical pitfalls: How blood collection tubes influence exercise‐induced cell‐free DNA concentrations

Experimental Physiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 3, 2025

Abstract Circulating cell‐free DNA (cfDNA) is a promising biomarker for physiological stress, including exercise‐induced responses. However, the lack of standardization in blood collection tubes (BCTs) quantification cfDNA hampers inter‐study comparisons. In this study, we assessed impact different BCTs on dynamics. Eleven participants [25 (SD 2.3) years age] performed three treadmill exercise protocols, an all‐out test and combinations constant interval load. Blood samples were collected before, 5 min 30 post‐exercise using EDTA, lithium–heparin (LH) serum BCTs. Concentrations quantified quantitative PCR. The increased significantly across all protocols A significant effect BCT concentrations ( P = 0.034) was found, with showing higher than EDTA LH. Although absolute differences from pre‐ to comparable 0.476), fold changes differed 0.012), highest observed lowest serum. Bland–Altman analyses demonstrated better agreement between LH compared Significant correlations energy expenditure peak oxygen uptake found. These stronger Our findings highlight crucial influence choice measurements settings. Given that reflected load better, they could be preferred physiology research. This work underscores need account improve data comparability studies. Additionally, these might have broader implications clinical settings where used as biomarker.

Language: Английский

---

LncRNA SNHG1: A novel biomarker and therapeutic target in hepatocellular carcinoma

Gene, Journal Year: 2025, Volume and Issue: unknown, P. 149462 - 149462

Published: April 1, 2025

Language: Английский

---

Diversity of the Circulating Tumor Markers: Perspectives of a Multimodal Liquid Biopsy

Biochemistry (Moscow), Journal Year: 2024, Volume and Issue: 89(11), P. 1985 - 1997

Published: Nov. 1, 2024

Language: Английский

---